<?php require("../scripts/template-start.php"); ?>

   <td class="title" valign=top>
		&nbsp;International Inquiries
   </td>

</tr>
<tr>
<td class="main">

<style>
    li {
        margin: 8px;
    }
</style>

<ul>
    <li>BabyBIG<sup>&reg;</sup> is available internationally on a case-by-case evaluation basis.  BabyBIG<sup>&reg;</sup> has been used to treat infants in Australia (2009), Europe (Spain 2007, United Kingdom 2007 and 2009, France 2007, Greece 2009, Portugal 2009, Ireland 2010 and Germany 2011-2012, Denmark 2011-2012), the Middle East (United Arab Emirates 2007), North America (Canada 2005-12) and South America (Argentina 2011).</li>
    <li>If used, BabyBIG<sup>&reg;</sup> should be given as soon as possible in the patient’s illness.  Do not delay requesting BabyBIG<sup>&reg;</sup> until laboratory confirmation of diagnosis is obtained.  Treatment within the first 3 days of hospitalization shortens the hospital stay the most.  Treatment between hospital days 4-7 also significantly shortens hospital stay when compared to placebo (N Engl J Med 2006;354:462-71).</li>
    <li>Access to BabyBIG<sup>&reg;</sup> is authorized only by one of the Infant Botulism Treatment and Prevention Program (IBTPP) on-call physicians, who must be contacted by the patient’s attending physician to discuss the clinical situation before BabyBIG<sup>&reg;</sup> can be shipped.</li>
    <li>An IBTPP on-call physician can be reached 24 hours a day, 7 days a week at exit calling code -1-510-231-7600.  </li>
    <li>The attending physician or hospital must obtain approval from their country’s Medicines Regulatory Authority (equivalent to the US Food and Drug Administration) to import BabyBIG<sup>&reg;</sup> because BabyBIG<sup>&reg;</sup> is licensed only in the US.</li>
    <li>Please be advised that the following steps are required for shipment and importation of BabyBIG<sup>&reg;</sup>: </li>
    <ul>
        <li>A letter of authorization to import must be provided to IBTPP by the requesting country’s Medicines Regulatory Authority or Agency before BabyBIG<sup>&reg;</sup> is released for shipment. </li>
        <li>BabyBIG<sup>&reg;</sup> will have to clear customs after arrival in the importing country. Arrangements to expedite customs clearance should be initiated as soon as BabyBIG<sup>&reg;</sup> is shipped.</li>
        <li>In addition to paying the statutorily required fee to CDPH for BabyBIG<sup>&reg;</sup>, the receiving hospital will also have to pay for the shipment of BabyBIG<sup>&reg;</sup> via an expedited courier service and for any customs charges.</li>
        <li>Before BabyBIG<sup>&reg;</sup> is released for shipment, IBTPP must receive
            <ol>
                <li> the signed Invoice and Purchase Agreement (IPA) document, which is available here, <a target="_blank" href="http://www.infantbotulism.org/physician/IPA-International-Spr2016.pdf">International Invoice and Purchase Agreement</a>.
                <li> medical records submitted either electronically or by fax that include documentation of the patient’s weight, and (to repeat)
                <li> the import permit authorization letter from the requesting country’s Medicines Regulatory Agency.  </li>
            </ol>
        </li>
    </ul>
    <li>Please call exit calling code -1-510-231-7600 at any time if you have any questions, and ask to speak to the doctor on-call.</li>
</ul>

</td>

<?php require("../scripts/template-end.php"); ?>
